ERBB2 and breast carcinoma: Traditional hormone-based therapy (i.e. tamoxifen to target EsR positive cells), and antibody-based therapy (i.e. trastuzumab to target Her2/Neu positive breast cancers) are not effective when treating TNBCs [4].